UVC-360

The importance of the BETR-D randomized clinical trial

Posted by Tru-D SmartUVC 08.08.19

slide-1-4_darkerIn the hierarchy of scientific studies, randomized clinical trials are some of the most highly-regarded. Until 2017, there had not been a randomized control trial on UVC disinfection in the health care setting.

The Benefits of Enhanced Terminal-Room Disinfection study, or BETR-D study, was the first to examine UVC disinfection and its effect on epidemiologically-important pathogens.

The $2 million study, which was funded by the Centers for Disease Control and Prevention, was conducted throughout nine hospitals of varying size and census in the Duke Infection Control Outreach Network from 2012-2014.

Researchers compared four different cleaning and disinfection scenarios: standard cleaning with quaternary ammonia; enhanced cleaning with quaternary ammonia and Tru-D; enhanced cleaning with bleach; and enhanced cleaning with bleach and Tru-D. Each hospital randomly rotated through the four cleaning protocols in each of the four, seven-month phases.

The BETR-D study tested Tru-D’s method of measured reflective dose and its impact on infection reduction in relation to other standard disinfection practices. The study measured the efficacy, effectiveness and feasibility of enhanced terminal room disinfection and correlated this data to its impact on health care-associated infections.

Tru-D was the only UVC device chosen for the BETR-D study which showed Tru-D was able to reduce the relative risk of colonization and infection caused by epidemiologically-important pathogens among patients admitted to the same room by a cumulative 30% in hospital settings with 93% compliance of standard disinfection protocols. Individual hospital results may vary.

“Our study is the first randomized trial to demonstrate that enhanced disinfection in the hospital can improve patient safety. This is not a debate anymore. The good news is that we can decrease that risk, and the best way is by using an enhanced strategy for cleaning.”

Deverick Anderson, MD, MPH

Lead Investigator, BETR-D Study, Duke Health

Stayed tuned to learn more about the study outcomes as well as barriers overcome with conducting the trial or click here for more information.

 

Posted 08.08.19
  • Share

Never miss the latest in UV news.
Subscribe to UVC360 today.

Sign Up »